Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans

Division of Cardiovascular Medicine, Stanford University School of Medicine, California 94305-5246, USA.

OBJECTIVES: The present study was designed to test the hypothesis that long-term dietary supplementation with the nitric oxide precursor L-arginine would enhance vascular or platelet-derived nitric oxide activity, or both, and thereby inhibit platelet reactivity in hypercholesterolemic humans. BACKGROUND: We have shown that reduced vascular activity of nitric oxide in hypercholesterolemic rabbits can be restored by L-arginine supplementation. The improvement in nitric oxide activity is associated with an inhibition of platelet aggregation ex vivo. This effect is most likely due to increased elaboration of endothelium- or platelet-derived nitric oxide, or both, because the inhibition of platelet reactivity was associated with elevation of intraplatelet cyclic guanosine monophosphate and was reversed by the nitric oxide synthase antagonist N-methyl-arginine. METHODS: In a double-blinded, randomized, placebo-controlled trial, hypercholesterolemic patients were assigned to L-arginine hydrochloride, 8.4 g/day orally, or placebo for 2 weeks. Platelet-rich plasma was obtained for aggregometry induced by collagen (1 to 10 micrograms/ml) at four points: baseline, after 2 weeks of treatment, after a 2-week washout and after a long-term washout of 16 weeks on average. Aggregation was quantified by light transmittance and expressed as a percent transmittance observed with platelet-poor plasma. RESULTS: Compared with normocholesterolemic control subjects, platelets from hypercholesterolemic subjects stimulated with 5 micrograms/ml of collagen showed increased aggregability (68.6% in hypercholesterolemic patients vs. 54.5% in normocholesterolemic control subjects, p < or = 0.02). After 2 weeks of treatment with L-arginine (but not placebo), platelet reactivity was modestly reduced; this effect persisted for 2 weeks after discontinuation of arginine (52.6% in arginine-treated patients vs. 65.1% in normocholesterolemic control subjects, p = 0.07). After 18 weeks (i.e., 16 weeks after discontinuing arginine treatment), the platelets of hypercholesterolemic patients once again became hyperaggregable, and the extent of platelet aggregation was significantly increased compared with the 4-week point (73.6% after vs. 52.6% during arginine treatment, p < 0.01). No significant change in platelet reactivity was seen in placebo-treated hypercholesterolemic patients throughout the study. L-Arginine treatment was well tolerated without side effects. CONCLUSIONS: This double-blinded, placebo-controlled study demonstrates that dietary supplementation with L-arginine can modestly attenuate the increased platelet reactivity seen in hypercholesterolemic patients. The data are consistent with our previous studies in hypercholesterolemic animals, demonstrating that L-arginine restores endogenous nitric oxide activity and inhibits platelet aggregation. Enhancement of endogenous nitric oxide activity is a potential novel therapeutic strategy worthy of further study.

This article has been cited by other articles:

				H. Akoglu, K. Agbaht, S. Piskinpasa, M. Y. Falay, F. Dede, G. Ozet, and A. R. Odabas High frequency of aspirin resistance in patients with nephrotic syndrome Nephrol. Dial. Transplant., August 23, 2011; (2011) gfr476v1. [Abstract] [Full Text] [PDF]

				A. I. Saleh, S. M. Abdel Maksoud, S. A. El-Maraghy, and M. Z. Gad Protective Effect of L-Arginine in Experimentally Induced Myocardial Ischemia: Comparison With Aspirin Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2011; 16(1): 53 - 62. [Abstract] [PDF]

				C. R. Morris Mechanisms of Vasculopathy in Sickle Cell Disease and Thalassemia Hematology, January 1, 2008; 2008(1): 177 - 185. [Abstract] [Full Text] [PDF]

				T. M.C. Brunini, A. C. Mendes-Ribeiro, J. C. Ellory, and G. E. Mann Platelet nitric oxide synthesis in uremia and malnutrition: A role for L-arginine supplementation in vascular protection? Cardiovasc Res, January 15, 2007; 73(2): 359 - 367. [Abstract] [Full Text] [PDF]

				J. H.K. Vogel, S. F. Bolling, R. B. Costello, E. M. Guarneri, M. W. Krucoff, J. C. Longhurst, B. Olshansky, K. R. Pelletier, C. M. Tracy, R. A. Vogel, et al. Integrating Complementary Medicine Into Cardiovascular Medicine: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (Writing Committee to Develop an Expert Consensus Document on Complementary and Integrative Medicine) J. Am. Coll. Cardiol., July 5, 2005; 46(1): 184 - 221. [Full Text] [PDF]

				R. A Anderson, G. R Ellis, L. M. Evans, K. Morris, Y. Y Chirkov, J. D Horowitz, S. K Jackson, A. Rees, M. J Lewis, and M. P Frenneaux Platelet nitrate responsiveness in fasting and postprandial type 2 diabetes Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 88 - 93. [Abstract] [PDF]

				S. G. West, A. Likos-Krick, P. Brown, and F. Mariotti Oral L-Arginine Improves Hemodynamic Responses to Stress and Reduces Plasma Homocysteine in Hypercholesterolemic Men J. Nutr., February 1, 2005; 135(2): 212 - 217. [Abstract] [Full Text] [PDF]

				H. L. Gornik and M. A. Creager Arginine and Endothelial and Vascular Health J. Nutr., October 1, 2004; 134(10): 2880S - 2887S. [Abstract] [Full Text] [PDF]

				J. P. Cooke Asymmetrical Dimethylarginine: The Uber Marker? Circulation, April 20, 2004; 109(15): 1813 - 1818. [Full Text] [PDF]

				H. Dayoub, V. Achan, S. Adimoolam, J. Jacobi, M. C. Stuehlinger, B.-y. Wang, P. S. Tsao, M. Kimoto, P. Vallance, A. J. Patterson, et al. Dimethylarginine Dimethylaminohydrolase Regulates Nitric Oxide Synthesis: Genetic and Physiological Evidence Circulation, December 16, 2003; 108(24): 3042 - 3047. [Abstract] [Full Text] [PDF]

				R. H Boger The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor Cardiovasc Res, October 1, 2003; 59(4): 824 - 833. [Abstract] [Full Text] [PDF]

				J. Niebauer, A. J. Maxwell, P. S. Lin, D. Wang, P. S. Tsao, and J. P. Cooke NOS inhibition accelerates atherogenesis: reversal by exercise Am J Physiol Heart Circ Physiol, July 11, 2003; 285(2): H535 - H540. [Abstract] [Full Text] [PDF]

				J. Sabate, E. Haddad, J. S Tanzman, P. Jambazian, and S. Rajaram Serum lipid response to the graduated enrichment of a Step I diet with almonds: a randomized feeding trial Am J Clin Nutr, June 1, 2003; 77(6): 1379 - 1384. [Abstract] [Full Text] [PDF]

				D. Tousoulis, C. Antoniades, C. Tentolouris, G. Goumas, C. Stefanadis, and P. Toutouzas L-Arginine in cardiovascular disease: dream or reality? Vascular Medicine, August 1, 2002; 7(3): 203 - 211. [Abstract] [PDF]

				G. Theilmeier, C. Michiels, E. Spaepen, I. Vreys, D. Collen, J. Vermylen, and M. F. Hoylaerts Endothelial von Willebrand factor recruits platelets to atherosclerosis-prone sites in response to hypercholesterolemia Blood, May 29, 2002; 99(12): 4486 - 4493. [Abstract] [Full Text] [PDF]

				E. B. Feldman The Scientific Evidence for a Beneficial Health Relationship Between Walnuts and Coronary Heart Disease J. Nutr., May 1, 2002; 132(5): 1062S - 1101. [Abstract] [Full Text] [PDF]

				M. A.W. Broeders, G. J. Tangelder, D. W. Slaaf, R. S. Reneman, and M. G.A. oude Egbrink Hypercholesterolemia Enhances Thromboembolism in Arterioles but Not Venules: Complete Reversal by L-Arginine Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 680 - 685. [Abstract] [Full Text] [PDF]

				Z. Kaposzta, P. A. Baskerville, D. Madge, S. Fraser, J. F. Martin, and H. S. Markus L-Arginine and S-Nitrosoglutathione Reduce Embolization in Humans Circulation, May 15, 2001; 103(19): 2371 - 2375. [Abstract] [Full Text] [PDF]

				R. H. Boger, S. M. Bode-Boger, P. S. Tsao, P. S. Lin, J. R. Chan, and J. P. Cooke An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes J. Am. Coll. Cardiol., December 1, 2000; 36(7): 2287 - 2295. [Abstract] [Full Text] [PDF]

				C. M. Oomen, M. J. van Erk, E. J. M. Feskens, F. J. Kok, and D. Kromhout Arginine Intake and Risk of Coronary Heart Disease Mortality in Elderly Men Arterioscler Thromb Vasc Biol, September 1, 2000; 20(9): 2134 - 2139. [Abstract] [Full Text] [PDF]

				A. J Maxwell, B. E Anderson, and J. P Cooke Nutritional therapy for peripheral arterial disease: a double-blind, placebo-controlled, randomized trial of HeartBar(R) Vascular Medicine, February 1, 2000; 5(1): 11 - 19. [Abstract] [PDF]

				E. C Ray, M. E Landis, and V. M Miller Effects of dietary l-arginine on the reactivity of canine coronary arteries Vascular Medicine, November 1, 1999; 4(4): 211 - 217. [Abstract] [PDF]

				J. Niebauer, S. P. Schwarzacher, M. Hayase, B. Wang, R. S. Kernoff, J. P. Cooke, and A. C. Yeung Local L-Arginine Delivery After Balloon Angioplasty Reduces Monocyte Binding and Induces Apoptosis Circulation, October 26, 1999; 100(17): 1830 - 1835. [Abstract] [Full Text] [PDF]

				G. Theilmeier, T. Lenaerts, C. Remacle, D. Collen, J. Vermylen, and M. F. Hoylaerts Circulating Activated Platelets Assist THP-1 Monocytoid/Endothelial Cell Interaction Under Shear Stress Blood, October 15, 1999; 94(8): 2725 - 2734. [Abstract] [Full Text] [PDF]

				H. Miyazaki, H. Matsuoka, J. P. Cooke, M. Usui, S. Ueda, S. Okuda, and T. Imaizumi Endogenous Nitric Oxide Synthase Inhibitor : A Novel Marker of Atherosclerosis Circulation, March 9, 1999; 99(9): 1141 - 1146. [Abstract] [Full Text] [PDF]

				O. Tangphao, S. Chalon, A. M Coulston, H. Moreno Jr, J. R Chan, J. P Cooke, B. B Hoffman, and T. F Blaschke L-arginine and nitric oxide-related compounds in plasma: comparison of normal and arginine-free diets in a 24-h crossover study Vascular Medicine, February 1, 1999; 4(1): 27 - 32. [Abstract] [PDF]

				W. H. Kaesemeyer, R. B. Caldwell, J. Huang, and R. W. Caldwell Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions J. Am. Coll. Cardiol., January 1, 1999; 33(1): 234 - 241. [Abstract] [Full Text] [PDF]

				R. H. Boger, S. M. Bode-Boger, A. Szuba, P. S. Tsao, J. R. Chan, O. Tangphao, T. F. Blaschke, and J. P. Cooke Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial Dysfunction : Its Role in Hypercholesterolemia Circulation, November 3, 1998; 98(18): 1842 - 1847. [Abstract] [Full Text] [PDF]

				J. K. Liao Endothelium and acute coronary syndromes Clin. Chem., August 1, 1998; 44(8): 1799 - 1808. [Abstract] [Full Text] [PDF]

				J. G. Diodati, N. Dakak, D. M. Gilligan, and A. A. Quyyumi Effect of Atherosclerosis on Endothelium-Dependent Inhibition of Platelet Activation in Humans Circulation, July 7, 1998; 98(1): 17 - 24. [Abstract] [Full Text] [PDF]

				M. de Lorgeril Dietary arginine and the prevention of cardiovascular diseases Cardiovasc Res, March 1, 1998; 37(3): 560 - 563. [Full Text] [PDF]

				M. A.W. Broeders, G. J. Tangelder, D. W. Slaaf, R. S. Reneman, and M. G.A. oude Egbrink Hypercholesterolemia Enhances Thromboembolism in Arterioles but Not Venules: Complete Reversal by L-Arginine Arterioscler Thromb Vasc Biol, April 1, 2002; 22(4): 680 - 685. [Abstract] [Full Text] [PDF]